Francisco J. Esteva
Francisco J. Esteva
Research Professor, NYU School of Medicine
Verified email at
Cited by
Cited by
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, ...
Cancer cell 6 (2), 117-127, 2004
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
R Nahta, D Yu, MC Hung, GN Hortobagyi, FJ Esteva
Nature clinical practice Oncology 3 (5), 269-280, 2006
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta, LXH Yuan, B Zhang, R Kobayashi, FJ Esteva
Cancer research 65 (23), 11118-11128, 2005
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer
J Baselga, V Semiglazov, P Van Dam, A Manikhas, M Bellet, ...
Journal of Clinical Oncology 27 (16), 2630-2637, 2009
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ...
Journal of Clinical Oncology 20 (7), 1800-1808, 2002
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ...
Journal of Clinical Oncology 19 (10), 2587-2595, 2001
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
CM Sturgeon, MJ Duffy, UH Stenman, H Lilja, N Brunner, DW Chan, ...
Clinical chemistry 54 (12), e11-e79, 2008
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta, MC Hung, FJ Esteva
Cancer research 64 (7), 2343-2346, 2004
Herceptin: mechanisms of action and resistance
R Nahta, FJ Esteva
Cancer letters 232 (2), 123-138, 2006
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor …
AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ...
Clinical Cancer Research 13 (1), 228-233, 2007
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ...
Nature medicine 17 (4), 461-469, 2011
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
AD Seidman, CA Hudis, J Albanell, J Albanel, W Tong, I Tepler, V Currie, ...
Journal of Clinical Oncology 16 (10), 3353-3361, 1998
HER2 therapy: molecular mechanisms of trastuzumab resistance
R Nahta, FJ Esteva
Breast Cancer Research 8 (6), 1-8, 2006
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615, 2012
Planning cancer control in Latin America and the Caribbean
PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ...
The Lancet Oncology 14 (5), 391-436, 2013
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience
V Guarneri, DJ Lenihan, V Valero, JB Durand, K Broglio, KR Hess, ...
Journal of Clinical Oncology 24 (25), 4107-4115, 2006
Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline
SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ...
Journal of clinical oncology 32 (19), 2078, 2014
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
J Clin Oncol 36 (24), 2465-2472, 2018
Residual risk of breast cancer recurrence 5 years after adjuvant therapy
AM Brewster, GN Hortobagyi, KR Broglio, SW Kau, CA Santa-Maria, ...
Journal of the National Cancer Institute 100 (16), 1179-1183, 2008
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta, T Takahashi, NT Ueno, MC Hung, FJ Esteva
Cancer research 64 (11), 3981-3986, 2004
The system can't perform the operation now. Try again later.
Articles 1–20